breast cancer

[Science] Researchers established a noncanonical function for small nuclear ribonucleoprotein polypeptide A′ (SNRPA1) and a previously unknown RNA structural code that regulated alternative splicing, and found that this SNRPA1-mediated pathway acted as a promoter of breast cancer metastasis.

[Molecular Therapy-Oncolytics] Researchers hypothesized that by creating an MHC independent vaccination, they would give rise to a sustained immune response against CD133 in triple negative breast carcinomas.

[Developmental Cell] The authors uncovered a dual role for Rank in the mammary epithelia: Rank induced senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.

[Veru, Inc.] Veru, Inc. announced that it has enrolled the first patient in its Phase III clinical trial of sabizabulin, a novel, proprietary, oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties, to combat the effects of COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2.

[Acta Pharmacologica Sinica] Scientists developed a bispecific antibody simultaneously targeting both PD1 and HER2 in an attempt to combine HER2-targeted therapy with immune checkpoint blockade for treating HER2-positive solid tumors.

[Cancer Discovery] Using integrated epigenomic, transcriptomic and proteomic analyses, researchers demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunological T cell memory.